Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ERIC 2020 | Why young scientists should attend ERIC 2020

Kostas Stamatopoulos • 16 Sep 2020
ERIC 2020
Chronic Lymphocytic Leukemia Leukemia

Kostas Stamatopoulos, MD, PhD, Center for Research and Technology Hellas, Thermi, Greece, discusses why young scientists from varying scientific backgrounds will benefit from attending ERIC 2020. This interview was recorded during an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Kostas Stamatopoulos

Translating scientific advances into clinical success in CLL: satellite symposium highlights 3:19
Translating scientific advances into clinical success in CLL: satellite symposium highlights
Kostas Stamatopoulos • 19 Mar 2022
The link between the tumor microenvironment & gene expression in CLL 2:02
The link between the tumor microenvironment & gene expression in CLL
Kostas Stamatopoulos • 19 Mar 2022
Pathogenesis and transformation in CLL: session highlights 1:46
Pathogenesis and transformation in CLL: session highlights
Kostas Stamatopoulos • 19 Mar 2022
The definition of high-risk CLL 2:54
The definition of high-risk CLL
Kostas Stamatopoulos • 19 Mar 2022

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals